Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Eli Lilly's GLP-1 franchise dominated first-quarter results, with Mounjaro and Zepbound delivering $12.8 billion in revenue—nearly two-thirds of total company sales. Mounjaro posted 125% year-over-year growth, marking an acceleration that prompted management to lift full-year 2026 guidance to a range of $82-85 billion.

The FDA's approval of Foundayo, a once-daily oral GLP-1, adds a new growth vector beyond the injectable formulations. The pill format targets patients who prefer oral administration, potentially expanding the addressable market beyond current users.

The concentration risk is stark: a single drug family now accounts for roughly 65% of Eli Lilly's revenue base. While the Mounjaro growth trajectory remains strong and the Foundayo launch provides optionality, any manufacturing hiccups, competitive pressure, or regulatory headwinds in the GLP-1 category would hit consolidated results hard.